addiction

Pharmalot By Ed Silverman

A pill to fight alcoholism causes an uproar in France over a regulator’s view of a clinical trial

First Opinion By David A. Patterson Silver Wolf

Real-time data are essential for Covid-19. They’re just as important for the opioid overdose crisis

Health By Lev Facher

Covid-19 has streamlined addiction medicine. Will the changes stick?

Pharmalot By Ed Silverman

Despite evidence, many primary care doctors don’t want to prescribe medications for addiction

First Opinion By Haider J. Warraich

What an 1890s opioid epidemic can teach us about ending addiction today

Business By Andrew Joseph

Prosecutors identified ‘Pharma Co. X’ as central to alleged opioid kickback scheme. Was it Purdue?

First Opinion By Lila Flavin and J. Wesley Boyd

A government database is supposed to help people seeking treatment for opioid addiction. It often doesn’t

Health By Andrew Joseph and Shraddha Chakradhar

Faced with prescriber fears of OxyContin misuse, Purdue sales reps misleadingly played up drug’s safety, documents show

Health Tech By Casey Ross

Pear Therapeutics licenses voice biomarkers for dementia and psychiatric disorders

First Opinion By William Stauffer

Addiction treatment is broken. Here’s what it should look like

Health By Lev Facher

This mental health advocate wants to make addiction and behavioral health a 2020 election issue

First Opinion By Lauren Lollini

A hospital staffer diverted drugs, which gave me hepatitis C. That happens more often than you think

Health By Andrew Joseph

National Academies outlines opioid guidelines, aiming to make approach to prescribing more consistent

First Opinion By Diane Dorman

Orphan Drug Act’s ‘nonprofitability’ loophole needs to be closed

Politics By Lev Facher

FDA blasts Alkermes for underselling the risks of opioid addiction drug Vivitrol

First Opinion By Patrick J. Kennedy

Mental health and addiction care are poorly covered by insurance networks

Health By Andrew Joseph

Tufts will scour Sackler name from its medical campus, in rebuff of family that controls Purdue Pharma

Exclusive By Casey Ross

Purdue’s Richard Sackler proposed plan to play down OxyContin risks, and wanted drug maker feared ‘like a tiger,’ files show

First Opinion By Judith Feinberg

The view from West Virginia: the end of HIV transmission is a distant dream

First Opinion By Alister Martin and Ted Robertson

Changing emergency doctors’ behaviors to promote wider use of medication for opioid use disorder

Pharma By David Armstrong — ProPublica

How Purdue planted its ‘anti-story’ and delayed the reckoning for its role in the opioid epidemic

Politics By Lev Facher

A new bill would let more doctors prescribe addiction treatments without waiting for insurers’ permission

Off the Charts By Jennifer Adaeze Okwerekwu

When it comes to health care, nothing is nonpartisan. Melania Trump’s visit to a Boston hospital harms patients and providers

Health By Andrew Joseph

With a new guide to tapering opioids, federal health officials seek a balanced approach to prescribing

Health By Shraddha Chakradhar

‘Sesame Street’ launches new initiative to help explain parental addiction to kids